CEO John Payne Reports Nearly $100K Open Market Stock Purchase
summarizeSummary
Zivo Bioscience's President and CEO, John Bernard Payne, purchased $99,995 worth of company stock in an open market transaction.
check_boxKey Events
-
CEO Increases Stake
John Bernard Payne, President and CEO of Zivo Bioscience, acquired 11,709 shares of common stock through an open market purchase on January 26, 2026.
-
Significant Insider Investment
The transaction totaled $99,995, representing a notable investment by the company's top executive at a price of $8.54 per share.
auto_awesomeAnalysis
Zivo Bioscience's President and CEO, John Bernard Payne, made a significant open market purchase of the company's common stock. This nearly $100,000 investment by the top executive signals strong confidence in the company's future prospects, especially for a nano-cap company where such an amount represents a material portion of the market capitalization. Insider buying, particularly from a CEO, is often viewed positively by investors as it aligns executive interests with shareholder value.
At the time of this filing, ZIVO was trading at $9.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $35M. The 52-week trading range was $6.95 to $22.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.